{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T08:51:02Z","timestamp":1761209462571,"version":"build-2065373602"},"reference-count":18,"publisher":"The Endocrine Society","issue":"11","license":[{"start":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T00:00:00Z","timestamp":1761177600000},"content-version":"vor","delay-in-days":28,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Predisposing Network for Tumorigenesis","award":["12375797"],"award-info":[{"award-number":["12375797"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,9,25]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>We present the case of a 40-year-old woman with severe recurrent hypoglycemia, unresponsive to dietary glucose intake and occurring in the context of chronic intestinal pseudo-obstruction, esophagojejunostomy, and long-term parenteral nutrition. Extensive endocrine and imaging evaluations excluded insulinoma, autoimmune hypoglycemia, and counterregulatory hormone deficiencies, suggesting impaired incretin function as the likely mechanism. Conventional treatments\u2014including acarbose, glucocorticoids, somatostatin analogues, and a long-acting glucagon-like peptide 1 receptor agonist (GLP-1 RA)\u2014failed to provide adequate glycemic control. Given the exclusion of the proximal duodenum from nutrient transit and its key role in glucose-dependent insulinotropic polypeptide (GIP) secretion, therapy with tirzepatide, a dual GIP\/GLP-1 receptor agonist, was initiated. Tirzepatide led to near-complete remission of hypoglycemic episodes and substantial improvement in glycemic variability and quality of life. Due to recurrence of symptoms before the next scheduled dose, the interval was shortened from 7 to 5 days, maintaining therapeutic efficacy. This case highlights the potential of tirzepatide in treating refractory hypoglycemia related to altered incretin signaling, particularly in patients with complex gastrointestinal surgical histories and parenteral nutrition. While currently approved for type 2 diabetes and obesity, tirzepatide may offer a novel off-label approach in select hypoglycemic syndromes in which GIP deficiency plays a central role.<\/jats:p>","DOI":"10.1210\/jcemcr\/luaf249","type":"journal-article","created":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T12:24:08Z","timestamp":1758716648000},"source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and Safety of Tirzepatide in Refractory Hypoglycemia Associated with Esophagojejunostomy"],"prefix":"10.1210","volume":"3","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-7331-3936","authenticated-orcid":false,"given":"Mariangela","family":"Caporusso","sequence":"first","affiliation":[{"name":"Endocrinology Unit, Regional General Hospital \u201cFrancesco Miulli,\u201d \u00a0 Acquaviva delle Fonti, IT 70021 Bari ,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-8165-7531","authenticated-orcid":false,"given":"Ludovico","family":"Di Gioia","sequence":"additional","affiliation":[{"name":"Endocrinology Unit, Regional General Hospital \u201cFrancesco Miulli,\u201d \u00a0 Acquaviva delle Fonti, IT 70021 Bari ,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4020-2825","authenticated-orcid":false,"given":"Mariangela","family":"Manicone","sequence":"additional","affiliation":[{"name":"Endocrinology Unit, Regional General Hospital \u201cFrancesco Miulli,\u201d \u00a0 Acquaviva delle Fonti, IT 70021 Bari ,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucrezia","family":"Matera","sequence":"additional","affiliation":[{"name":"Endocrinology Unit, Regional General Hospital \u201cFrancesco Miulli,\u201d \u00a0 Acquaviva delle Fonti, IT 70021 Bari ,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7372-2678","authenticated-orcid":false,"given":"Francesco","family":"Giorgino","sequence":"additional","affiliation":[{"name":"Department of Precision and Regenerative Medicine and Ionian Area, Section of Internal Medicine, Endocrinology, Andrology and Metabolic Diseases, University of Bari Aldo Moro , IT 70124 Bari ,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2728-7721","authenticated-orcid":false,"given":"Sebastio","family":"Perrini","sequence":"additional","affiliation":[{"name":"Endocrinology Unit, Regional General Hospital \u201cFrancesco Miulli,\u201d \u00a0 Acquaviva delle Fonti, IT 70021 Bari ,","place":["Italy"]},{"name":"Section of Endocrinology, Department of Medicine and Surgery, Libera Universit\u00e0 Mediterranea (LUM) , Casamassima, IT 70010 Bari ,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"80","published-online":{"date-parts":[[2025,10,23]]},"reference":[{"issue":"3","key":"2025102304461623100_luaf249-B1","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1210\/jc.2008-1410","article-title":"Evaluation and management of adult hypoglycemic disorders: an Endocrine Society clinical practice guideline","volume":"94","author":"Cryer","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"2025102304461623100_luaf249-B2","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1038\/s41574-020-0357-5","article-title":"International consensus on the diagnosis and management of dumping syndrome","volume":"16","author":"Scarpellini","year":"2020","journal-title":"Nat Rev Endocrinol"},{"issue":"6","key":"2025102304461623100_luaf249-B3","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/S2213-8587(15)00482-9","article-title":"The incretin effect in healthy individuals and those with type 2 diabetes: physiology, pathophysiology, and response to therapeutic interventions","volume":"4","author":"Nauck","year":"2016","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"6","key":"2025102304461623100_luaf249-B4","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.tem.2020.02.006","article-title":"How may GIP enhance the therapeutic efficacy of GLP-1?","volume":"31","author":"Samms","year":"2020","journal-title":"Trends Endocrinol Metab"},{"issue":"1","key":"2025102304461623100_luaf249-B5","doi-asserted-by":"crossref","first-page":"e12945","DOI":"10.1111\/nmo.12945","article-title":"Chronic intestinal pseudo-obstruction in children and adults: diagnosis and therapeutic options","volume":"29","author":"Di Nardo","year":"2017","journal-title":"Neurogastroenterol Motil"},{"issue":"3","key":"2025102304461623100_luaf249-B6","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1002\/psp4.13099","article-title":"Population pharmacokinetics of the GIP\/GLP receptor agonist tirzepatide","volume":"13","author":"Schneck","year":"2024","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"17","key":"2025102304461623100_luaf249-B7","doi-asserted-by":"crossref","first-page":"e140532","DOI":"10.1172\/jci.insight.140532","article-title":"Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist","volume":"5","author":"Willard","year":"2020","journal-title":"JCI Insight"},{"key":"2025102304461623100_luaf249-B8","author":"Athavale"},{"issue":"12","key":"2025102304461623100_luaf249-B9","doi-asserted-by":"crossref","first-page":"3118","DOI":"10.1007\/s11695-017-2734-2","article-title":"Hypoglycemia following bariatric surgery: our 31-year experience","volume":"27","author":"Michaels","year":"2017","journal-title":"Obes Surg"},{"issue":"9","key":"2025102304461623100_luaf249-B10","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.2337\/db16-0341","article-title":"Gastric bypass reduces symptoms and hormonal responses in hypoglycemia","volume":"65","author":"Abrahamsson","year":"2016","journal-title":"Diabetes"},{"issue":"3","key":"2025102304461623100_luaf249-B11","first-page":"442","article-title":"Hypoglycemia post bariatric surgery: drugs with different mechanisms of action to treat a unique disorder","volume":"67","author":"Carpentieri","year":"2023","journal-title":"Arch Endocrinol Metab"},{"issue":"3","key":"2025102304461623100_luaf249-B12","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1056\/NEJMoa2206038","article-title":"Tirzepatide once weekly for the treatment of obesity","volume":"387","author":"Jastreboff","year":"2022","journal-title":"N Engl J Med"},{"issue":"10295","key":"2025102304461623100_luaf249-B13","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S0140-6736(21)01324-6","article-title":"Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial","volume":"398","author":"Rosenstock","year":"2021","journal-title":"Lancet"},{"issue":"1","key":"2025102304461623100_luaf249-B14","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/s44324-024-00030-5","article-title":"Incretin-based therapies for the treatment of obesity-related diseases","volume":"2","author":"Caruso","year":"2024","journal-title":"NPJ Metab Health Dis"},{"key":"2025102304461623100_luaf249-B15","doi-asserted-by":"crossref","first-page":"102181","DOI":"10.1016\/j.eclinm.2023.102181","article-title":"Glucometabolic outcomes of GLP-1 receptor agonist-based therapies in patients with type 2 diabetes: a systematic review and network meta-analysis","volume":"64","author":"Caruso","year":"2023","journal-title":"EClinicalMedicine"},{"key":"2025102304461623100_luaf249-B16","doi-asserted-by":"crossref","first-page":"101090","DOI":"10.1016\/j.molmet.2020.101090","article-title":"Glucagon-like peptide-1 receptor co-agonists for treating metabolic disease","volume":"46","author":"Baggio","year":"2021","journal-title":"Mol Metab"},{"issue":"6","key":"2025102304461623100_luaf249-B17","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1038\/s42255-023-00811-0","article-title":"The incretin co-agonist tirzepatide requires GIPR for hormone secretion from human islets","volume":"5","author":"El","year":"2023","journal-title":"Nat Metab"},{"issue":"11","key":"2025102304461623100_luaf249-B18","doi-asserted-by":"crossref","first-page":"luae194","DOI":"10.1210\/jcemcr\/luae194","article-title":"Tirzepatide improves early dumping syndrome and glucose nadir in postbariatric hypoglycemia after sleeve gastrectomy","volume":"2","author":"Stortz","year":"2024","journal-title":"JCEM Case Rep"}],"container-title":["JCEM Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jcemcr\/article-pdf\/3\/11\/luaf249\/64877444\/luaf249.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcemcr\/article-pdf\/3\/11\/luaf249\/64877444\/luaf249.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T08:46:27Z","timestamp":1761209187000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcemcr\/article\/doi\/10.1210\/jcemcr\/luaf249\/8299912"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,25]]},"references-count":18,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,9,25]]}},"URL":"https:\/\/doi.org\/10.1210\/jcemcr\/luaf249","relation":{},"ISSN":["2755-1520"],"issn-type":[{"value":"2755-1520","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,11]]},"published":{"date-parts":[[2025,9,25]]},"article-number":"luaf249"}}